What is the place of thrombolysis in acute stroke? A review of the literature and a current perspective

被引:7
作者
Jenkins, Peter O. [1 ]
Turner, Martin R. [2 ]
Jenkins, Paul F. [3 ,4 ]
机构
[1] Guys & St Thomas Hosp, Fdn Year 1, London SE1 9RT, England
[2] John Radcliffe Hosp, Oxford OX3 9DU, England
[3] Univ Western Australia, Perth, WA 6009, Australia
[4] Joondalup Hlth Campus, Perth, WA, Australia
关键词
cerebral haemorrhage; cerebral infarction; cost effectiveness; stroke; thrombolysis; tissue plasminogen activator;
D O I
10.7861/clinmedicine.8-3-253
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The global burden of stroke, the undisputed success of intravenous thrombolysis in the management of myocardial infarction and subsequent evidence from animal models of cerebral infarction have all fuelled intense interest in the potential role for thrombolytic agents in the acute management of stroke in clinical practice. Before any clinical treatment is introduced universally its safety and efficacy must be demonstrated in the routine clinical environment and not just within the ideal conditions of controlled clinical trials. Similarly, the cost effectiveness of a new treatment modality is an essential consideration before its use is promulgated. This paper reviews the current scientific evidence for thrombolysis in stroke with reference to issues of safety, efficacy and cost effectiveness.
引用
收藏
页码:253 / 258
页数:6
相关论文
共 52 条
  • [11] RECOMBINANT TISSUE PLASMINOGEN-ACTIVATOR IN ACUTE THROMBOTIC AND EMBOLIC STROKE
    DELZOPPO, GJ
    POECK, K
    PESSIN, MS
    WOLPERT, SM
    FURLAN, AJ
    FERBERT, A
    ALBERTS, MJ
    ZIVIN, JA
    WECHSLER, L
    BUSSE, O
    GREENLEE, R
    BRASS, L
    MOHR, JP
    FELDMANN, E
    HACKE, W
    KASE, CS
    BILLER, J
    GRESS, D
    OTIS, SM
    [J]. ANNALS OF NEUROLOGY, 1992, 32 (01) : 78 - 86
  • [12] DONALDSON C, 1991, BRIT MED J, V235, P891
  • [13] DONNAN GA, 1995, LANCET, V345, P578
  • [14] DONNAN GA, 1996, JAMA-J AM MED ASSOC, V276, P966
  • [15] Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke
    Fagan, SC
    Morgenstern, LB
    Petitta, A
    Ward, RE
    Tilley, BC
    Marler, JR
    Levine, SR
    Broderick, JP
    Kwiatkowski, TG
    Frankel, M
    Brott, TG
    Walker, MD
    [J]. NEUROLOGY, 1998, 50 (04) : 883 - 890
  • [16] Intra-arterial prourokinase for acute ischemic stroke - The PROACT II study: A randomized controlled trial
    Furlan, A
    Higashida, R
    Wechsler, L
    Gent, M
    Rowley, H
    Kase, C
    Pessin, M
    Ahuja, A
    Callahan, F
    Clark, WM
    Silver, F
    Rivera, F
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (21): : 2003 - 2011
  • [17] Dose escalation of desmoteplase for acute ischemic stroke (DEDAS) - Evidence of safety and efficacy 3 to 9 hours after stroke onset
    Furlan, AJ
    Eyding, D
    Albers, GW
    Al-Rawi, Y
    Lees, KR
    Rowley, HA
    Sachara, C
    Soehngen, M
    Warach, S
    Hacke, W
    [J]. STROKE, 2006, 37 (05) : 1227 - 1231
  • [18] The Desmoteplase In Acute Ischemic Stroke Trial (DIAS) - A phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase
    Hacke, W
    Albers, G
    Al-Rawi, Y
    Bogousslavsky, J
    Davalos, A
    Eliasziw, M
    Fischer, M
    Furlan, A
    Kaste, M
    Lees, KR
    Soehngen, M
    Warach, S
    [J]. STROKE, 2005, 36 (01) : 66 - 73
  • [19] Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II)
    Hacke, W
    Kaste, M
    Fieschi, C
    von Kummer, R
    Davalos, A
    Meier, D
    Larrue, V
    Bluhmki, E
    Davis, S
    Donnan, G
    Schneider, D
    Diez-Tejedor, E
    Trouillas, P
    [J]. LANCET, 1998, 352 (9136) : 1245 - 1251
  • [20] HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017